Immunovia announces determined exercise price for warrants series TO 3
Immunovia AB has announced the exercise price for its warrants series TO 3 at SEK 0.24 per share. The exercise period runs from April 1-15, 2025, with trading available until April 11, 2025. The warrants were issued as part of a Rights Issue in August-September 2024, where each unit consisted of two shares, two TO 2 warrants, and one TO 3 warrant.
If all 62,211,989 warrants are exercised, Immunovia will raise approximately SEK 14.9 million before costs. The subscription price was set at 70% of the volume-weighted average price during March 14-27, 2025. Upon full exercise, the company's share capital will increase by SEK 1,866,359.67 to SEK 9,723,625.56, with total outstanding shares rising from 261,908,863 to 324,120,852, representing a dilution of approximately 19.2%.
Immunovia AB ha annunciato il prezzo di esercizio per i suoi warrant serie TO 3 a SEK 0,24 per azione. Il periodo di esercizio va dal 1 al 15 aprile 2025, con la possibilità di negoziazione fino all'11 aprile 2025. I warrant sono stati emessi come parte di un'emissione di diritti tra agosto e settembre 2024, dove ogni unità era composta da due azioni, due warrant TO 2 e un warrant TO 3.
Se tutti i 62.211.989 warrant vengono esercitati, Immunovia raccoglierà circa SEK 14,9 milioni prima dei costi. Il prezzo di sottoscrizione è stato fissato al 70% del prezzo medio ponderato per volume durante il periodo dal 14 al 27 marzo 2025. Con l'esercizio completo, il capitale sociale dell'azienda aumenterà di SEK 1.866.359,67 a SEK 9.723.625,56, con il numero totale di azioni in circolazione che passerà da 261.908.863 a 324.120.852, rappresentando una diluizione di circa il 19,2%.
Immunovia AB ha anunciado el precio de ejercicio para sus warrants serie TO 3 a SEK 0,24 por acción. El período de ejercicio va del 1 al 15 de abril de 2025, con la posibilidad de negociación hasta el 11 de abril de 2025. Los warrants se emitieron como parte de una emisión de derechos en agosto-septiembre de 2024, donde cada unidad consistía en dos acciones, dos warrants TO 2 y un warrant TO 3.
Si se ejercen todos los 62.211.989 warrants, Immunovia recaudará aproximadamente SEK 14,9 millones antes de costos. El precio de suscripción se estableció en el 70% del precio medio ponderado por volumen durante el período del 14 al 27 de marzo de 2025. Con el ejercicio completo, el capital social de la empresa aumentará en SEK 1.866.359,67 a SEK 9.723.625,56, con el número total de acciones en circulación aumentando de 261.908.863 a 324.120.852, lo que representa una dilución de aproximadamente el 19,2%.
Immunovia AB는 TO 3 시리즈의 워런트 행사 가격을 SEK 0.24로 발표했습니다. 행사 기간은 2025년 4월 1일부터 15일까지이며, 거래는 2025년 4월 11일까지 가능합니다. 이 워런트는 2024년 8월에서 9월 사이에 실시된 권리 공모의 일환으로 발행되었으며, 각 유닛은 두 개의 주식, 두 개의 TO 2 워런트, 그리고 하나의 TO 3 워런트로 구성되었습니다.
모든 62,211,989 개의 워런트가 행사될 경우, Immunovia는 비용 전 약 SEK 14.9 백만을 모금하게 됩니다. 구독 가격은 2025년 3월 14일부터 27일까지의 거래량 가중 평균 가격의 70%로 설정되었습니다. 모든 워런트가 행사되면 회사의 자본금은 SEK 1,866,359.67 증가하여 SEK 9,723,625.56이 되며, 총 발행 주식 수는 261,908,863주에서 324,120,852주로 증가하여 약 19.2%의 희석을 나타냅니다.
Immunovia AB a annoncé le prix d'exercice de ses warrants de série TO 3 à SEK 0,24 par action. La période d'exercice s'étend du 1er au 15 avril 2025, avec la possibilité de négociation jusqu'au 11 avril 2025. Les warrants ont été émis dans le cadre d'une émission de droits en août-septembre 2024, où chaque unité était composée de deux actions, deux warrants TO 2 et un warrant TO 3.
Si tous les 62.211.989 warrants sont exercés, Immunovia lèvera environ SEK 14,9 millions avant coûts. Le prix de souscription a été fixé à 70 % du prix moyen pondéré par volume pendant la période du 14 au 27 mars 2025. En cas d'exercice complet, le capital social de l'entreprise augmentera de SEK 1.866.359,67 à SEK 9.723.625,56, le nombre total d'actions en circulation passant de 261.908.863 à 324.120.852, représentant une dilution d'environ 19,2 %.
Immunovia AB hat den Ausübungspreis für seine Warrants der Serie TO 3 auf SEK 0,24 pro Aktie bekannt gegeben. Der Ausübungszeitraum läuft vom 1. bis 15. April 2025, mit Handel bis zum 11. April 2025. Die Warrants wurden im Rahmen einer Bezugsrechtsemission im August-September 2024 ausgegeben, wobei jede Einheit aus zwei Aktien, zwei TO 2 Warrants und einem TO 3 Warrant bestand.
Wenn alle 62.211.989 Warrants ausgeübt werden, wird Immunovia etwa SEK 14,9 Millionen vor Kosten aufbringen. Der Bezugspreis wurde auf 70% des volumengewichteten Durchschnittspreises vom 14. bis 27. März 2025 festgelegt. Bei vollständiger Ausübung wird das Grundkapital des Unternehmens um SEK 1.866.359,67 auf SEK 9.723.625,56 steigen, wobei die Gesamtzahl der ausgegebenen Aktien von 261.908.863 auf 324.120.852 steigen wird, was eine Verwässerung von etwa 19,2% darstellt.
- Potential to raise SEK 14.9 million in additional capital
- 19.2% shareholder dilution upon full warrant exercise
- Low warrant exercise price of SEK 0.24 indicates weak share price performance
Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. If all warrants are exercised, Immunovia will receive approximately
The subscription price for the warrants was set at 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period 14 – 27 March 2025, however not more than an amount corresponding to 150 percent of the subscription price per share in the Rights Issue (
Summary of instructions and important dates
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at the latest on 15 April 2025. Warrants that have not been exercised on or before 15 April 2025 expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including 11 April 2025.
Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 15 April 2025 as different nominees have different processing times.
Exercise of directly registered warrants
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Vator Securities AB, no later than 15 April 2025.
The application form is available on the Company's and Vator Securities AB's respective websites (www.immunovia.com and www.vatorsecurities.se). Please note that payment for the new shares must be received by Vator Securities no later than 15 April 2025 in accordance with the instructions on the application form.
Trading in TO 3
Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm. The warrants are traded up to and including 11 April 2025 under the short name IMMNOV TO 3 and with ISIN code SE0022600102. Warrants that are not exercised on 15 April 2025 at the latest will expire without value.
Outcome and delivery of new ordinary shares
The outcome of the exercise of warrants will be published via a press release on or around 17 April 2025. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Immunovia.
Change in share capital and number of shares
Upon full exercise of all 62,211,989 warrants series TO 3, the share capital will increase by a maximum of
Complete terms and conditions for the warrants
Complete terms and conditions for the warrants are available on the Company's website, www.immunovia.com.
Advisers
Vator Securities AB acts as financial adviser to Immunovia in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
The information was submitted for publication, through the agency of the contact persons set out above, at 20:40 CET on 27 March 2025.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Immunovia. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Immunovia has only been made through the prospectus published by Immunovia on 12 August 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.immunovia.com.
Since Immunovia is considered to carry out protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company's website, www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press releae (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-announces-determined-exercise-price-for-warrants-series-to-3-302413671.html
SOURCE Immunovia AB
FAQ
What is the exercise price for Immunovia (IMMVF) TO 3 warrants in 2025?
When is the exercise period for Immunovia's TO 3 warrants?
How much capital can Immunovia raise from the TO 3 warrants exercise?
What is the dilution impact of Immunovia's TO 3 warrants on existing shareholders?
How many TO 3 warrants were issued by Immunovia?
